Neutropenia is graded into three levels based on how far the absolute neutrophil count (ANC) drops below normal, and each level carries a meaningfully different risk of infection. The dividing lines sit at 1,500, 1,000, and 500 cells per microliter of blood, with anything below 500 considered severe. Those thresholds are not arbitrary cutoffs; they track real jumps in the likelihood of bacterial and fungal infections, and understanding them helps make sense of the treatment decisions that follow a low blood count.
The Three Grades and What Each One Means
A normal ANC for most adults falls somewhere between roughly 1,500 and 7,000 cells per microliter. Once the count dips below 1,500, clinicians assign a grade based on how low it goes:
- Mild (ANC 1,000–1,500): Infection risk is minimal at this level, and the neutropenia often resolves on its own without any specific treatment.
- Moderate (ANC 500–1,000): The immune system is noticeably weakened. Infections of the skin and mucous membranes become more likely, and closer monitoring is warranted.
- Severe (ANC below 500): The risk of serious opportunistic infections climbs sharply. Bacterial and fungal bloodstream infections, pneumonia, and painful mouth ulcers all become realistic threats.
These thresholds come up repeatedly in oncology because chemotherapy is one of the most common triggers, but the grading system applies regardless of cause. Whether the low count comes from a medication, an autoimmune process, or a genetic condition, the infection risk at each level is comparable.
1PubMed Central. Diagnosis and management of neutropenia – Section: Classification of neutropenia and managementWhy Duration Matters as Much as Depth
Grading captures the depth of neutropenia, but depth alone does not tell the whole story. How long the count stays low turns out to be just as important. A patient whose ANC dips below 500 for two days after a chemotherapy cycle faces a very different situation from someone whose count stays below 500 for two weeks.
Research on patients receiving chemotherapy for solid tumors and blood cancers has quantified this relationship. Each additional day spent at severe-grade neutropenia was associated with roughly a 30 percent increase in the risk of being hospitalized for an infection.2PubMed. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies That compounding effect is why clinicians pay close attention to the trajectory of the count over days, not just the single lowest reading. A brief dip into severe territory with a quick rebound is far less dangerous than a prolonged nadir.
The practical upshot is that the 500-cell threshold acts as a kind of danger line: staying above it substantially lowers infection risk, while remaining below it for an extended stretch drives risk higher and higher.3International Journal of Research in Medical Sciences. Risk estimates and features of infectious events in subjects with different causes and level of neutropenia This is why oncologists sometimes delay or reduce chemotherapy doses when recovery from the previous cycle is slow. Keeping the severe window as short as possible is a core goal of supportive care.
Febrile Neutropenia Is Its Own Category
When a neutropenic patient develops a fever, the situation gets a separate label: febrile neutropenia. It is generally defined as a fever of at least 38 °C (about 100.4 °F) in a patient with an ANC below 1,000.4PubMed. Emergency department evaluation of early warning scores in predicting mortality in febrile neutropenia patients This combination is treated as a medical emergency because, in someone with very few functioning neutrophils, fever may be the only outward sign that an infection is underway. The typical inflammatory responses that generate redness, swelling, and pus all depend on neutrophils, so many of the usual warning signs of infection are muted or absent.
Febrile neutropenia is most often a complication of chemotherapy, and it demands immediate antibiotic treatment regardless of whether a specific infection source has been identified. Waiting for culture results before starting antibiotics can allow a bloodstream infection to spiral quickly.5PubMed Central. Management and Preventive Measures for Febrile Neutropenia Risk-scoring tools exist to help clinicians figure out which febrile neutropenia patients are likely to do well with oral antibiotics at home versus those who need intravenous treatment in the hospital, but the universal first step is the same: start antibiotics fast.
What Causes Neutropenia in the First Place
The grading system applies the same way no matter why the count is low, but the causes themselves vary widely and influence how long the neutropenia is expected to last and how aggressively it needs to be managed.
Chemotherapy and Other Medications
Cytotoxic chemotherapy is the single most common cause of clinically significant neutropenia. These drugs suppress the bone marrow’s ability to produce new blood cells, and neutrophils, which have a short lifespan in the bloodstream to begin with, are among the first to drop.6PubMed. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management The nadir typically hits a week or two after a treatment cycle, then counts slowly recover as the marrow regenerates.
Chemotherapy is not the only medication culprit. A range of non-chemotherapy drugs can also push neutrophil counts down, sometimes severely. The mechanisms appear to involve either direct toxicity to the cells that produce neutrophils in the bone marrow or an immune reaction that destroys circulating neutrophils.7PubMed. Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit? Certain antithyroid drugs, antipsychotics, and antibiotics are among the better-known offenders. When a non-chemotherapy drug is the cause, stopping the medication usually allows the count to recover, though recovery can take days to weeks depending on how deeply the marrow was suppressed.
Autoimmune Destruction
In autoimmune neutropenia, the body’s immune system produces antibodies that target neutrophils, marking them for destruction. These antibodies cause both a drop in neutrophil numbers and, in some cases, impaired function in the neutrophils that remain.8PubMed Central. Primary and secondary autoimmune neutropenia In infants and young children, this condition (often called autoimmune neutropenia of infancy) is the most common form. The antibodies typically target a specific receptor on the neutrophil surface, causing the cells to be cleared from circulation faster than the marrow can replace them.9PubMed Central. Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians The good news is that the childhood form tends to resolve on its own within a year or two.
In adults, autoimmune neutropenia can occur as a standalone condition or alongside other autoimmune diseases like lupus or rheumatoid arthritis. Bone marrow biopsies in adult patients sometimes reveal a striking finding: macrophages in the marrow actively engulfing mature neutrophils, driven by the antibodies coating those cells.10PubMed Central. Phagocytosis of Mature Granulocytes by Bone Marrow Macrophages in an Elderly Man with Adult-Onset Primary Autoimmune Neutropenia
Congenital Forms
Some people are born with genetic mutations that impair neutrophil production from the start. The most well-characterized of these involve a gene called ELANE, which encodes an enzyme known as neutrophil elastase. Mutations in ELANE are responsible for both severe congenital neutropenia and cyclic neutropenia, a condition in which the count rises and falls in roughly three-week cycles.11PubMed Central. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology
In a large screening study, ELANE mutations were found in about 41 percent of patients with severe congenital neutropenia and 55 percent of patients with cyclic neutropenia, making it the single most common genetic cause of both conditions. Interestingly, the mutations associated with cyclic neutropenia tend to be somewhat milder in their predicted effects on the protein than those linked to the severe congenital form, though there is substantial overlap.12PubMed. The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia
Benign Ethnic Neutropenia Is Not Really a Disease
One of the most clinically important nuances in grading neutropenia is that “normal” ANC values vary by ethnicity. Many people of African, Middle Eastern, and West Indian descent have baseline neutrophil counts that fall below the standard 1,500 threshold used to define neutropenia. This condition, called benign ethnic neutropenia, affects a large number of individuals worldwide and is not associated with any increased risk of infection.13PubMed Central. Benign ethnic neutropenia
The problem arises when standard grading thresholds are applied without accounting for this variation. A person with benign ethnic neutropenia might consistently have an ANC around 1,200, which technically qualifies as mild neutropenia by the usual scale. If a clinician does not recognize this as a normal baseline for that individual, they might delay chemotherapy, withhold a needed medication, or launch an unnecessary diagnostic workup. Awareness of benign ethnic neutropenia is especially critical in oncology, where treatment decisions often hinge on whether the ANC has recovered enough to proceed with the next cycle.
Boosting Neutrophil Counts with Growth Factors
When neutropenia is severe or prolonged, particularly after chemotherapy, growth factor medications can help the bone marrow produce neutrophils faster. The most widely used is G-CSF (granulocyte colony-stimulating factor), sold under names like filgrastim. The FDA approved G-CSF for treating both congenital and acquired neutropenias, as well as for mobilizing stem cells for transplantation. A longer-acting pegylated version is also available, allowing less frequent dosing.14PubMed Central. G-CSF and GM-CSF in Neutropenia
In patients with chronic severe neutropenia, long-term G-CSF therapy has been studied extensively. Patients with congenital neutropenia typically start with the lowest pre-treatment neutrophil counts and require the highest doses of G-CSF compared to those with cyclic or autoimmune forms. Across all groups, treatment raises the ANC, though the degree of response varies by the underlying cause.15Blood Advances. Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor For chemotherapy patients, G-CSF is often given prophylactically after cycles known to cause deep or prolonged neutropenia, with the goal of shortening the window of vulnerability.
Preventive Antibiotics and the Neutropenic Diet Myth
For patients expected to have prolonged severe neutropenia, preventive antibiotics play a well-established role. Fluoroquinolone antibiotics are recommended for patients receiving chemotherapy for blood cancers or high-dose regimens for solid tumors when neutropenia below 500 is expected to last longer than a week.16PubMed Central. Prevention of febrile neutropenia: use of prophylactic antibiotics For those at the highest risk, including patients expected to have counts below 100 for more than a week, professional guidelines recommend both antibacterial and antifungal prophylaxis, along with antiviral medications for patients known to carry herpes simplex virus.17Journal of Oncology Practice. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary
One area where practice has lagged behind evidence is the so-called “neutropenic diet.” For decades, many hospitals told neutropenic patients to avoid fresh fruits, raw vegetables, and certain other uncooked foods, on the theory that these could introduce dangerous bacteria. The evidence, however, does not support this restriction. A randomized trial of 150 pediatric cancer patients found no difference in infection rates between those on a restrictive neutropenic diet and those simply following standard food safety guidelines.18PubMed. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients A systematic review confirmed the finding more broadly: the neutropenic diet does not reduce infections or deaths among cancer patients. The review concluded that standard food-safety practices, like proper hand-washing, cooking meats thoroughly, and avoiding obviously spoiled food, are sufficient.19PubMed. Lack of Efficacy of the Neutropenic Diet in Decreasing Infections among Cancer Patients: A Systematic Review Despite this, some institutions continue to enforce the diet out of tradition.
When the Lab Result Is Wrong
Not every low neutrophil count reflects what is actually happening inside the body. A lab artifact called pseudoneutropenia can make it look like the count is low when it is not. One well-documented cause is the anticoagulant EDTA, which is used in standard blood-collection tubes. In rare cases, EDTA triggers neutrophils to clump together in the tube after the blood is drawn. The automated counter then misses the clumped cells, producing a falsely low reading.20PubMed. EDTA-induced pseudo-neutropenia resolved with kanamycin
This matters clinically because a spurious low count could lead to unnecessary interventions: delayed chemotherapy, unneeded bone marrow biopsies, or anxious monitoring of a problem that does not exist. If a low ANC does not match the patient’s clinical picture (they feel fine, have no infections, and their other blood counts are normal), requesting a manual review of the blood smear or re-drawing the sample into a different type of tube can resolve the discrepancy.
Neutropenia in Newborns
Neutropenia in newborns deserves its own mention because the normal range for neutrophil counts in neonates is different from that in older children and adults, and the causes are distinct. In premature babies and critically ill newborns, neutropenia is relatively common and often tied to conditions like maternal high blood pressure, neonatal sepsis, twin-to-twin transfusion, or immune-mediated destruction from maternal antibodies crossing the placenta.21PubMed Central. Neutropenia in the newborn Interpreting a low count in a neonate requires age-specific reference ranges; applying adult thresholds can lead to either missed diagnoses or unnecessary alarm.
Living with Chronic Neutropenia
For people who live with chronic severe neutropenia, whether from a congenital condition, autoimmune disease, or another cause, the impact extends well beyond infection risk. The largest study to date examining quality of life in these patients found that adults with chronic severe neutropenia scored significantly worse than healthy controls on measures of overall quality of life, fatigue, physical function, cognitive function, and pain. Depression was also more common.22PubMed. Quality of life and patient-reported outcomes in chronic severe neutropenia conditions
Children with chronic neutropenia showed a different pattern. Their quality-of-life scores were comparable to healthy peers, and they actually reported fewer depressive symptoms, better mobility, and stronger peer relationships than controls. The reasons for this discrepancy between children and adults are not fully understood, but it may reflect the cumulative burden of managing a chronic condition over many years, or it may be that children with neutropenia adapt more readily because they have never known a different baseline. Adults and children alike, however, reported high satisfaction with their medical providers, rating them as compassionate and accessible. The findings underscore that managing chronic neutropenia well means addressing the psychological and functional toll, not just monitoring the ANC and prescribing growth factors.